Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
Ken OkumuraMasaharu AkaoTetsuro YoshidaMasahito KawataOsamu OkazakiShintaro AkashiKenichi EshimaKimihiko TanizawaMasayuki FukuzawaTakuya HayashiMasahiro AkishitaGregory Y H LipTakeshi Yamashitanull nullPublished in: The New England journal of medicine (2020)
In very elderly Japanese patients with nonvalvular atrial fibrillation who were not appropriate candidates for standard doses of oral anticoagulants, a once-daily 15-mg dose of edoxaban was superior to placebo in preventing stroke or systemic embolism and did not result in a significantly higher incidence of major bleeding than placebo. (Funded by Daiichi Sankyo; ELDERCARE-AF ClinicalTrials.gov number, NCT02801669.).
Keyphrases
- atrial fibrillation
- oral anticoagulants
- low dose
- middle aged
- left atrial
- catheter ablation
- venous thromboembolism
- left atrial appendage
- direct oral anticoagulants
- community dwelling
- heart failure
- double blind
- phase iii
- percutaneous coronary intervention
- physical activity
- risk factors
- placebo controlled
- randomized controlled trial
- clinical trial
- coronary artery disease
- blood brain barrier
- brain injury